rgp120/hiv-1 sf-2
Vaccineexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000832)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rgp120/hiv-1 sf-2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000749 | Phase 1 | Nov 2, 1999 | Chiron, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000832 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000871 | Phase 2 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001019 | Phase 1 | Nov 2, 1999 | Chiron, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001031 | Phase 2 | Nov 2, 1999 | Chiron, Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001042 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00001046 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000774 | Phase 1 | — | Chiron, Genentech, National Institute of Allergy and Infectious Diseases (NIAID), New York University |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 8 | 8 | 2 | 1999 |
| Chiron | For profit | 4 | 0 | 2 | 1999 |
| Genentech | For profit | 2 | 0 | 2 | 1999 |
| New York University | Academic/Hospital | 1 | 0 | 1 | — |
4 organizations
Page 1 / 1